Table 4.
Demographic and clinical features and mental health scale results in patients with or without increased disease related symptoms in LP.
| Features | Patients with increased symptoms (n = 22) | Patients without increased symptoms (n = 38) | p |
|---|---|---|---|
| Age (years) (mean ± SD) | 40.09 ± 7.99 | 45.63 ± 10.42 | 0.036 |
| Gender | |||
| Female (n,%) | 15 (68.2%) | 19 (50%) | 0.171 |
| Male (n,%) | 7 (31.8%) | 19 (50%) | |
| Body mass index (kg/m2) (mean ± SD) | 27.72 ± 4.90 | 26.46 ± 4.82 | 0.336 |
| Smoking habits (n,%) | 13 (59.1%) | 25 (65.8%) | 0.604 |
| Type of mastocytosis | |||
| CM (n,%) | 2 (9.1%) | 3 (7.9%) | 0.872 |
| ISM (n,%) | 18 (81.8%) | 32 (84.2%) | 0.811 |
| AdvSM (n,%) | 2 (9.1%) | 3 (7.9%) | 0.872 |
| Comorbid diseases | |||
| Diabetes mellitus (n,%) | 2 (9.1%) | 7 (18.4%) | 0.329 |
| Hypertension (n,%) | 3 (13.6%) | 10 (26.3) | 0.251 |
| Hyperlipidemia (n,%) | 2 (9.1%) | 2 (5.3%) | 0.567 |
| Hypothyroidism (n,%) | 1 (4.5%) | 2 (5.3%) | 0.902 |
| Malignancy (n, %) | 1 (4.5%) | 1 (2.6%) | 0.691 |
| Duration of diseases (years) (median, IQR 25–75) | 6 (3–9.5) | 4.5 (3–6.25) | 0.479 |
| Serum baseline tryptase level (kU/L) (median, IQR 25–75) | 26 (14.2–38) | 22.7 (11.7–60) | 0.948 |
| FCV-19S (mean ± SD) | |||
| LP | 26.36 ± 4.59 | 18.00 ± 7.20 | <0.001 |
| RTNP | 18.23 ± 3.93 | 14.13 ± 5.85 | 0.005 |
| tDASS-21 (median, IQR 25–75) | |||
| LP | 21 (13.75–31.75) | 3 (0–6.5) | <0.001 |
| RTNP | 2.5 (2.5–5.25) | 0 (0–0) | <0.001 |
| DASS-21 DS (median, IQR 25–75) | |||
| LP | 3.5 (1–7.5) | 0 (0–1) | 0.001 |
| RTNP | 0 (0–1) | 0 (0–0) | 0.003 |
| DASS-21 AS (median, IQR 25–75) | |||
| LP | 9.5 (5.75–12.25) | 1 (0–4) | <0.001 |
| RTNP | 0 (0–1.25) | 0 (0–0) | 0.013 |
| DASS-21 SS (median, IQR 25–75) | |||
| LP | 9 (7.75–11.25) | 0.5 (0–3) | <0.001 |
| RTNP | 1.5 (0–4) | 0 (0–0) | <0.001 |
AdvSM, Advanced Systemic Mastocytosis; AS, Anxiety subscale; CM, Cutaneous mastocytosis; DS, Depression subscale; FCV-19S, Fear of COVID-19 scale; IQR, Interquartile range; ISM, Indolent Systemic Mastocytosis; LP, Lockdown period; SD, Standard deviation; SS, Stress subscale; RTNP, Return to Normal period; tDASS-21, Total depression, anxiety, stress scale with 21 questions.
P values <0.05 in bold is considered significant.